Tag: Solid Tumors
-
Astellas Secures Option on Audax’s IL-12 Cancer Therapy DAX-044
Astellas secured an option to license Audax’s DAX-044, a preclinical IL-12 immunotherapy designed to focus immune activation within the tumor microenvironment.
Astellas secured an option to license Audax’s DAX-044, a preclinical IL-12 immunotherapy designed to focus immune activation within the tumor microenvironment.